Ziprasidone is an atypical antipsychotic, with higher ratio of 5-HT2A/D2, 5-HT2C/D2 and 5-HT1A/D2 receptor binding than other antipsychotic drugs (Schmidt et al. 2001; Stahl and Shayegan 2007) . It also blocks the serotonin transporter (5-HTT) and inhibits synaptic 5-HT reuptake (Tatsumi et al. 1999) . Drugs that block the 5-HTT such as selective serotonin reuptake inhibitors (SSRI) have antidepressant properties, and ziprasidone is reported to have antidepressant effects in patients with depression (Moeller et al. 2007; Stahl and Shayegan 2007) . At present, however, it is unknown whether ziprasidone affects the 5-HTT in vivo when given to patients in therapeutic doses. Platelet 5-HT concentration is a reliable marker of the 5-HTT blockade induced by SSRI, and reduced platelet 5-HT concentration is used as a marker of the biological activity of various SSRI (Muck-Seler et al. 2002) . Therefore, the aim of the study was to investigate the effect of ziprasidone treatment on platelet 5-HT concentration in patients with schizophrenia or schizoaffective disorders. The hypothesis was that, if ziprasidone blocks 5-HTT, it will reduce platelet 5-HT concentration.
An open-label, flexible-dose study included 21 (eight female and 13 male) patients with schizophrenia or schizoaffective disorder treated with ziprasidone (109.0±27.1 mg/day, range 80-160), diagnosed using Structured Clinical Interview based on DSM-IV criteria, who were hospitalized due to inefficacy or adverse events of previous antipsychotic medication, or who stopped taking their antipsychotics prior to hospitalization. Exclusion criteria: treatment with ziprasidone, SSRI, tricyclic antidepressants or any other drug known to affect serotonin uptake in previous 4 weeks, past adverse reactions to ziprasidone, dementia, any other organic mental disorder, severe psychosis, severe depression, substance abuse and dependence in previous 3 months, abnormal ECG, and the corrected (QTc) interval exceeding 450 ms. Benzodiazepines and hypnotics were allowed throughout the study. Anticholinergics were not routinely prescribed, but were allowed in the case of the emergence of extrapyramidal symptoms. The study was approved by the Ethics Committee of the University Hospital Centre Zagreb, and has therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki. All subjects have signed written informed consent. Efficacy assessment was done using the Positive and Negative Syndrome Scale PANSS, Clinical Global Impression of Severity (CGI-S), and Calgary Depression Symptom scale (CDSS). Ratings were performed on baseline (within 24 h before the first application of study drug), at the end of the 7 and 28 days of treatment. Three patients dropped out from the study and their basal samples were therefore excluded: two patients required SSRI treatment, and one patient withdrew consent. The following adverse events were reported during the study period: insomnia (N=2), headache (N=3), agitation (N=2), and muscular rigidity (N=1). Blood samples (8 ml) were collected into plastic syringes with 2 ml of acid citrate dextrose anticoagulant at 08.00 h. The determination of the platelet 5-HT concentration was done in platelet rich plasma using spectrofluorimetric method, as previously described (Muck-Seler et al. 1999) . The results were expressed as means±SD. Statistical evaluation of the data was done using one-way analysis of variance (ANOVA), followed by the Tukey's multiple comparison test, and with multiple regression analysis. The level of significance was set at p=0.05.
Platelet 5-HT concentration did not differ significantly [F(5, 57)=0.298, p=0.912] between eight female and 13 male schizophrenic patients before, and after 7 and 28 days of ziprasidone treatment (Table 1 To the best of our knowledge, no data on the effect of ziprasidone on platelet 5-HT concentration is yet available, and we have found the lack of effect of 7 and 28 days of treatment with ziprasidone (109 mg/day) on platelet 5-HT concentration in male or female schizophrenic patients. Ziprasidone treatment did not reduce platelet 5-HT concentration, and this finding might be explained by the suboptimal antidepressant dose of ziprasidone, although lower doses were also reported to be effective (Moeller et al. 2007) , and the clinical effects of ziprasidone on symptoms of schizophrenia and depression were achieved with these lower doses (present study; Daniel et al. 1999 ). We could speculate that ziprasidone might have shown an inhibitory effect on platelet 5-HT concentration if prescribed in higher doses (Daniel et al. 1999) . Although ziprasidone has the highest potency for human 5-HTT (Kd=39 nM) among atypical antipsychotics, its Kd is substantially weaker than that of SSRI paroxetine (Kd= 0.13 nM), (Tatsumi et al. 1999) , which was reported to reduce platelet 5-HT concentration after 28 days of treatment in depressed patients (Muck-Seler et al. 2002) . The explanation of the antidepressant effect of ziprasidone might be due to other mechanisms, such as noradrenalin and dopamine reuptake blocking properties (Tatsumi et al. 1999) , or 5HT2A, 5HT2C and 5HT7 blocking properties (Schmidt et al. 2001; Stahl and Shayegan 2007) . Although gender (Muck-Seler et al. 1999) , smoking and age (Nenadic-Sviglin et al. 2011 ) significantly affected platelet 5-HT concentration in our previous studies, the present study failed to detect a significant effect of these variables on platelet 5-HT concentration. Limitations of the study are that patients receiving ziprasidone were not randomized, the number of included subjects was small, blood ziprasidone concentration was not measured and patient compliance was not checked. However, since all patients were hospitalized during the whole trial, ziprasidone intake was controlled by nurses.
In conclusion, ziprasidone did not significantly affect platelet 5-HT concentration in male and female schizophrenic patients. These findings strongly argue against our hypothesis that ziprasidone significantly affects 5-HT reuptake in vivo. 
